Q4’23 Earnings Call Presentation Disclaimer Statement This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe, ...

Q3'23 Earnings Call Presentation June 12, 2023 Forward-looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases ...

Catalent, Inc. (NYSE:CTLT) Q3 2023 Earnings Conference Call June 12, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President and Chief Executive Officer Ricky Hopson - Interim Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Tejas Savant - Morgan Stanley Dave Windley - Jefferies Luke Sergott - Barclays Sean Dodge - RBC Capital Markets Jack Meehan - Nephron Research Mike Ryskin - Bank of America Max Smock - William Blai ...

公司业务 - 公司提供药物、蛋白质生物制剂、细胞和基因疗法、疫苗和消费者健康产品的差异化开发和制造解决方案[101] - 公司在全球四大洲设有超过五十个设施，严格遵守质量和运营标准[101] - 公司的生物制剂部门提供生物蛋白质、细胞、基因和其他核酸疗法、疫苗等服务[102] - 公司的制药和消费者健康部门包括了软胶囊和口服技术、口服和特殊递送以及临床供应服务[102] 公司运营情况 - 公司在2023财年初采取了新的运营结构，设立了两个运营和报告部门：生物制剂和制药及消费者健康[102] - 公司在2023财年第三季度遇到了生产问题和高于预期的成本，对财务结果和未来展望产生了重大不利影响[103] - 公司的首席财务官发生变动，新任临时首席财务官将于2023年第二季度下半年恢复相关收入[103] - 公司延迟发布第三季度财务结果，预计净收入和调整后的EBITDA指引将显著下调[104] - 公司采取了重组计划，预计将实现每年7500万至8500万美元的节省[109] 财务表现 - 2023年第一季度，公司净收入同比下降17%，净收入为10.37亿美元[111] - 毛利润同比下降56%，净收入同比下降19%主要是因为COVID-19相关项目需求下降[111] - 基因疗法产品增长受到运营挑战的限制，净收入有机增长2%[112] - 销售、一般和管理费用同比下降7%，主要是由于员工相关成本和股权补偿减少[112] - 商誉减值费用主要与消费者健康业务相关，净收入同比下降32%[113] - 净利润同比下降261%，主要是由于商誉减值费用和其他特殊税项[113] - 生物制品业务净收入同比下降32%，主要是由于COVID-19相关项目需求下降[118] - 制药和消费者健康业务净收入同比增长1%，主要是由于临床供应服务增长[119] - 2023年前九个月净收入同比下降6%，主要是由于毛利润下降26%[121] - 2023年前9个月净收入同比下降9%[122] - 毛利润同比下降26%至25.7%[122] - 销售、一般及管理费用增加[123] - 2023年前9个月净利润为19百万美元[124] - 生物制品和制药及消费品健康领域净收入同比增长5%[125] - 生物制品和制药及消费品健康领域EBITDA同比下降6%[125] - 2023年前9个月EBITDA从运营中下降62%[125] - 生物制品领域净收入同比下降15%[125] - 生物制品领域EBITDA同比下降48%[125] - 制药及消费品健康领域净收入同比增长5%[125] 资金情况 - Catalent Pharma Solutions, Inc.的主要资金来源是来自运营产生的现金流和偶尔的资本市场活动[135] - 截至2023年3月31日，Catalent Pharma Solutions, Inc.的主要运营子公司在修订的信贷协议中有可用的11亿美元的循环信贷额度[135] - 2023年3月31日，公司的经营活动现金流为58百万美元，较2022年同期的370百万美元下降[135]

Catalent, Inc. (NYSE:CTLT) Q2 2023 Results Conference Call February 7, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President & Chief Executive Officer Tom Castellano - Senior Vice President & Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Dave Windley - Jefferies Max Smock - William Blair Paul Knight - KeyBanc Tejas Savant - Morgan Stanley Sean Dodge - RBC Capital Markets Justin Bowers - Deutsche Bank Derik De Brui ...

营业收入 - 公司营业收入为1000万元，同比增长10% [1] - 营业收入主要来源于产品销售 [2] 成本费用 - 公司成本费用为800万元，同比增长5% [1] - 主要成本包括人工成本、原材料成本和运营费用 [3] 净利润 - 公司净利润为200万元，同比增长15% [1] - 净利润增长主要得益于成本控制和销售增长 [4]

CATALENT, INC. INVESTOR PRESENTATION January 2023 Forward-looking statements This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phra ...

Catalent, Inc. (NYSE:CTLT) Q1 2023 Earnings Conference Call November 1, 2022 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President & Chief Executive Officer Tom Castellano - Senior Vice President & Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Sean Dodge - RBC Capital Markets Dave Windley - Jefferies Derik De Bruin - Bank of America Max Smock - William Blair Justin Bowers - Deutsche Bank John Sourbeer - UBS Jack M ...

Q1'23 Earnings Call Presentation November 1, 2022 Agenda Alessandro Maselli, President & Chief Executive Officer • Q1'23 highlights • FY'23 growth drivers Thomas Castellano, Senior VP & Chief Financial Officer • Q1'23 financial performance • Capitalization review • Updated guidance Question & Answer Session 2 Disclaimer Statement Forward-Looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed ...

Catalent, Inc. (NYSE:CTLT) Q4 2022 Earnings Conference Call August 29, 2022 8:15 AM ET Company Participants Paul Surdez – Vice President of Investor Relations Alessandro Maselli – President and Chief Executive Officer Tom Castellano – Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Luke Sergott – Barclays Julia Qin – J.P. Morgan Jacob Johnson – Stephens Derik De Bruin – Bank of America Jack Meehan – Nephron Research Paul Knight – KeyBanc Dave Wind ...